Historically, researchers have had to make trade-offs between sensitivity and specificity when choosing antibodies. Recombinant antibodies provide a solution, with many advantages over traditional hybridoma derived antibodies.

Role of Custom Antibodies in Neurological Disorders to monoclonal antibodies, recombinant antibodies are produced in vitro using synthetic genes introduced into mammalian cells. This animal-free process eliminates the need for hybridoma cell immunization and enables a quicker production time (a few weeks vs. months). The specificity and sensitivity of recombinant antibodies is enhanced because they are generated from a single clone of antibody-producing B cells. Recombinant antibodies also benefit from greater batch-to-batch consistency because their antibody gene sequence is well-defined and not subject to genetic drift.

Protein Expression Services Explained: Choosing the Right Platform for Your Project

In addition, recombinant antibodies are available in multiple formats. We can produce recombinant antibodies in single chain variable fragments (scFv) format, Fab (fragment antigen-binding), or bispecific forms (FabscFv).

For crystallography studies, recombinant antibodies are preferred due to their higher stability and reliability than hybridoma derived antibodies. In addition, recombinant antibodies require less purification to obtain milligram quantities needed for crystallization.

Recombinant antibodies are also an excellent choice for immunotherapy and therapeutic applications. Several antibody therapeutics targeting PD-1/PD-L1 have already entered clinical trials, highlighting the potential of this class of drugs. Recombinant antibodies can be used to prevent binding of PD-1/PD-L1 ligands to their receptors, thus blocking the immune checkpoint response and slowing tumor growth.